Valneva Announces Positive Phase 1 Trial Results for Zika Vaccine Candidate VLA1601.

Valneva SE has reported positive results from its Phase 1 clinical trial of VLA1601, a second-generation adjuvanted inactivated vaccine candidate against Zika virus. The trial enrolled 150 participants aged 18-49 and evaluated two doses of the vaccine, with additional adjuvants tested in a low dose. The results showed an improved immune response, with high levels of antibodies detected in all groups. The trial will continue to assess the safety and efficacy of VLA1601.